Bicycle Therapeutics (Bicycle Therapeutics) Equity-to-Asset : 0.65 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bicycle Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bicycle Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $356.05 Mil. Bicycle Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $547.14 Mil. Therefore, Bicycle Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.65.

The historical rank and industry rank for Bicycle Therapeutics's Equity-to-Asset or its related term are showing as below:

BCYC' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.86 Med: 0.64 Max: 0.85
Current: 0.65

During the past 7 years, the highest Equity to Asset Ratio of Bicycle Therapeutics was 0.85. The lowest was -0.86. And the median was 0.64.

BCYC's Equity-to-Asset is ranked worse than
51.86% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs BCYC: 0.65

Bicycle Therapeutics Equity-to-Asset Historical Data

The historical data trend for Bicycle Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicycle Therapeutics Equity-to-Asset Chart

Bicycle Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.85

0.59

0.72

0.66

0.62

Bicycle Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial															0.57	0.49	0.65	0.62	0.65

Competitive Comparison of Bicycle Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Bicycle Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Equity-to-Asset falls into.

Bicycle Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bicycle Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	370.932	/	595.344
	=	0.62

Bicycle Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	356.048	/	547.143
	=	0.65

Bicycle Therapeutics (NAS:BCYC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Bicycle Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bicycle Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicycle Therapeutics (Bicycle Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicycle Therapeutics PLC (NAS:BCYC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

50BA:Germany

Address

Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS

Website

https://www.bicycletherapeutics.com

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Executives

Nigel Crockett	officer: Chief Business Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Travis Alvin Thompson	officer: Chief Accounting Officer	C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE X0 CB21 6GS
Alistair Milnes	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Kevin Lee	director, officer: Chief Executive Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Nicholas Keen	officer: Chief Scientific Officer	C/O BICYCLE THEAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Michael Skynner	officer: Chief Operating Officer	C/O BICYCLE THERAPEUTICS LIMITED, B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB223AT
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Lee Kalowski	officer: President and CFO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Santiago Arroyo	officer: Chief Development Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Dominic Smethurst	officer: Chief Medical Officer	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Kate Bingham	director	1365 MAIN STREET, WALTHAM MA 02451
Jose-carlos Gutierrez-ramos	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098